Latest Information Update: 21 Aug 2007
At a glance
- Originator Regeneron Pharmaceuticals
- Class Carrier proteins
- Mechanism of Action Bone morphogenetic protein-4 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Fibrodysplasia ossificans progressiva
Most Recent Events
- 27 Nov 2000 Preclinical development for Fibrodysplasia ossificans progressiva in USA (unspecified route)